Tefibazumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTefibazumab
Drug Alias NameAurexisHumanised mAb 12-9 - InhibitexStaphylococcus aureus monoclonal antibody - InhibitexS. aureus monoclonal antibody - InhibitexINH-H2002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpithelial cell adhesion molecule inhibitorsImmunostimulants
TargetsEpithelial cell adhesion molecule
Therapy Area/IndicationsStaphylococcal InfectionsBacteremia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsN/A
Inactive IndicationsStaphylococcal InfectionsBacteremia

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG